Day One Biopharmaceuticals (DAWN) Enterprise Value (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed Enterprise Value for 4 consecutive years, with -$441.1 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 17.04% to -$441.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$441.1 million, a 17.04% increase, with the full-year FY2025 number at -$441.1 million, up 17.04% from a year prior.
- Enterprise Value was -$441.1 million for Q4 2025 at Day One Biopharmaceuticals, up from -$451.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$262.7 million in Q1 2022 to a low of -$558.4 million in Q3 2024.
- A 4-year average of -$405.6 million and a median of -$397.2 million in 2022 define the central range for Enterprise Value.
- Biggest YoY gain for Enterprise Value was 19.13% in 2025; the steepest drop was 48.77% in 2025.
- Day One Biopharmaceuticals' Enterprise Value stood at -$342.3 million in 2022, then dropped by 7.03% to -$366.3 million in 2023, then plummeted by 45.14% to -$531.7 million in 2024, then increased by 17.04% to -$441.1 million in 2025.
- Per Business Quant, the three most recent readings for DAWN's Enterprise Value are -$441.1 million (Q4 2025), -$451.6 million (Q3 2025), and -$453.1 million (Q2 2025).